The drugs industry is an enormous multibillion businesses encompassing an immense number of companies involved in the design, production and marketing of drugs worldwide. According to the type of drugs the market can be dived into the following segments: diabetes, antifungal, antidepressant, antithrombotic, hepatitis drugs, analgesics and a far more.
Currently, the drugs market is undergoing a recovery phase in the wake of the recent decline provoked by the economic slump. The market growth is spurred by increasing demand for drugs across the globe, rising incidence of chronic as well as infectious diseases, population ageing, product innovations and constant technological advancements. North America and Europe are the most prominent regional markets. Bristol-Myers Squibb, Pharmacia, GlaxoSmithKline, Merck & Co, Novartis, Eli Lilly, Pfizer, Johnson & Johnson, Allergan, Schering-Plough, Bayer and Abbott Labs are amid global drugs arena giants.
A huge collection of the research reports covering the drugs market at different geographies can be found under this MarketPublishers’ catalogue. The researches provide comprehensive assessment of the market, characterize major market trends and disclose essential market indicators. The reports describe the competitive scenario and indicate top market players. In addition, future prospects for the drugs market are thoroughly studied in the research reports.
Publications found:
9,295
Sort by:
Dystrophin (DMD) - Drugs In Development, 2021
US$ 3,500.00
Dystrophin (DMD) - Drugs In Development, 2021 SUMMARY According to the recently published report 'Dystrophin - Drugs In Development, 2021'; Dystrophin (DMD) pipeline Target constitutes close to 57 mol...
June 2021
161 pages
Exportin 1 - Drugs In Development, 2021
US$ 3,500.00
Exportin 1 - Drugs In Development, 2021 SUMMARY Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) pipeline Target constitutes close to 10 molecules. Out of which approximately 10 mo...
June 2021
143 pages
Gonorrhea (Infectious Disease) - Drugs In Development, 2021
US$ 2,000.00
Gonorrhea (Infectious Disease) - Drugs In Development, 2021 SUMMARY Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gonorrhea (Infectious Disease) - Drugs In Develo...
June 2021
127 pages
Gorlin Syndrome (Oncology) - Drugs In Development, 2021
US$ 2,000.00
Gorlin Syndrome (Oncology) - Drugs In Development, 2021 SUMMARY Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gorlin Syndrome (Oncology) - Drugs In Development, 2...
June 2021
186 pages
Iduronate 2 Sulfatase - Drugs In Development, 2021
US$ 3,500.00
Iduronate 2 Sulfatase - Drugs In Development, 2021 SUMMARY According to the recently published report 'Iduronate 2 Sulfatase - Drugs In Development, 2021'; Iduronate 2 Sulfatase (Alpha L Iduronate Sul...
June 2021
75 pages
Leukotriene A 4 Hydrolase - Drugs In Development, 2021
US$ 3,500.00
Leukotriene A 4 Hydrolase - Drugs In Development, 2021 SUMMARY Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A4 Hydrolase or LTA4H or EC 3.3.2.6) pipeline Target constitutes close to 6 mol...
June 2021
50 pages
Myocarditis (Cardiovascular) - Drugs In Development, 2021
US$ 2,000.00
Myocarditis (Cardiovascular) - Drugs In Development, 2021 SUMMARY Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Myocarditis (Cardiovascular) - Drugs In Developmen...
June 2021
57 pages
Pressure Ulcers (Dermatology) - Drugs In Development, 2021
US$ 2,000.00
Pressure Ulcers (Dermatology) - Drugs In Development, 2021 SUMMARY Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pressure Ulcers (Dermatology) - Drugs In Developm...
June 2021
30 pages
Pruritus (Dermatology) - Drugs In Development, 2021
US$ 2,000.00
Pruritus (Dermatology) - Drugs In Development, 2021 SUMMARY Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pruritus (Dermatology) - Drugs In Development, 2021, pro...
June 2021
221 pages
Restenosis (Cardiovascular) - Drugs In Development, 2021
US$ 2,000.00
Restenosis (Cardiovascular) - Drugs In Development, 2021 SUMMARY Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Restenosis (Cardiovascular) - Drugs In Development,...
June 2021
40 pages
Tyrosine Protein Kinase Mer - Drugs In Development, 2021
US$ 3,500.00
Tyrosine Protein Kinase Mer - Drugs In Development, 2021 SUMMARY According to the recently published report 'Tyrosine Protein Kinase Mer - Drugs In Development, 2021'; Tyrosine Protein Kinase Mer (Pro...
June 2021
94 pages
Investigation Report on China's Anlotinib Market 2021-2025
US$ 2,600.00
Anlotinib is an oral multi-targeting small-molecule tyrosine kinase inhibitor that can target multiple angiogenic factor receptors to inhibit tumor angiogenesis. It can be used for advanced non-small...
June 2021
50 pages
